Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics, Inc. a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors.

Dr. Min Wang has over 20 years of experience in the biotech space where she has operated as a business and legal advisor to the board and senior management at private and publicly traded companies through different phases of their organizational lifecycle. Dr. Wang most recently served as COO at Monte Rosa Therapeutics, where she held broad management responsibilities for key corporate functions. Previously, Dr. Wang served as COO of BlueRock Therapeutics through its acquisition by Bayer in 2019. Prior to BlueRock, Dr. Wang held the position of Senior VP, General Counsel and Corporate Secretary of Agios Pharmaceuticals. Earlier in her career, Dr. Wang served in roles of increasing responsibility in legal and IP functions at Genentech and Merck. Dr. Wang received her PhD in Organic Chemistry from Brown University and a JD from Fordham University School of Law.